Carmat (PAR: ALCAR)

Last close As at 21/12/2024

8.61

−0.08 (−0.92%)

Market capitalisation

EUR195m

Carmat is developing a biocompatible, artificial heart to satisfy the lack of donor hearts available for terminal heart failure patients. The development process combines the expertise of a wide range of technical and medical experts.

Latest Insights

View More

Healthcare | edison tv

Carmat: Edison Open House Healthcare 2022

Healthcare | Update

Carmat — Implantation momentum

Healthcare | edison tv

Carmat – Edison Open House interview

Healthcare | edison tv

Carmat – executive interview with Stéphane Piat

Research

edison tv

Healthcare

Carmat – executive interview with Stéphane Piat

Update

Healthcare

Carmat — CE Mark achieved, launching in Q2

Update

Healthcare

Carmat — Development progressing in the US and EU

Outlook

Healthcare

Carmat — Full-year results and clinical updates

edison tv

Healthcare

Executive Interview – Carmat

Flash note

Healthcare

Carmat — Carmat obtains clearance to resume pivotal study

Flash note

Healthcare

Carmat — Update 1 December 2016

Further insights

insight

Healthcare

Total Artificial Hearts

Thematics

thematic

Healthcare

Healthcare-focused trusts: A sector on the mend

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free